A Review on Major Depressive Disorder

By
Mumtahina Sadia
19146056

A thesis submitted to the School of Pharmacy in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (Hons.)

School of Pharmacy
Brac University
November 2023

Declaration

It is now declared that

1. The thesis submitted is my original work while completing my degree at Brac University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through complete and accurate referencing.
3. The thesis does not contain material that has been accepted or submitted for any other degree or diploma at a university or other institution.
4. I have acknowledged all primary sources of help.

Mumtahina Sadia
19146056

Approval

The thesis/project titled "A Review on Major Depressive Disorder" submitted by Mumtahina Sadia (19146056) of Spring 2023, has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy.

Supervised By:

_____

Luluel Maknun Fariha
Lecturer
School of Pharmacy
Brac University

Approved By:

Program Director:

_____

Professor Dr. Hasina Yasmin
Program Director and Assistant Dean
School of Pharmacy
Brac University

Dean:

_____

Professor Dr. Eva Rahman Kabir
Dean
School of Pharmacy
Brac University

Ethics Statement

This review did not involve any human and animal trials.

Abstract

Major depressive disorder is a severe mental health condition that causes mood swings in only one or two weeks. Anyone may experience this, and MDD can strike people of any age for a variety of causes. It's a potentially fatal illness characterized by low mood, disinterest, impaired thinking, and vegetative signs such erratic eating or sleeping habits. Stress, traumatic experiences as a youngster, or anything else might trigger it. If the patient is not receiving treatment, MDD may become worse. Consultation may be used to treat it. Antidepressants such as TCA, MAOI, SSRI, SNRI, and others are used to treat MDD. In addition to this, physical activity is beneficial. This study provides a general overview of MDD, the current status of targeted therapy for the treatment of MDD, as well as an analysis of the challenges this approach confronts and potential solutions.

Keywords: Major depressive disorder, SSRI, SNRI, TCA, MDD, MAOI, SMD.

Dedication

I want to dedicate this project to my parents for their endless support and encouragement.

Acknowledgment

My greatest thanks and appreciation go out to my project supervisor, Luluel Maknun Fariha (Lecturer, Brac University School of Pharmacy), whose knowledge, willingness to spend a lot of time, and constant direction at every turn have enabled me to complete my research successfully. I want to express my gratitude to her for all of her help throughout this time, both in terms of counsel and patience when I needed it.

Furthermore, I would like to extend my sincere gratitude to Dr. Eva Rahman Kabir, Professor and Dean of School of Pharmacy, Brac University for everything that she does for the students and the department. Furthermore, I would want to thank, Professor Dr. Hasina Yasmin, Program Director and Assistant Dean, School of Pharmacy, Brac University, Namara Mariam Chowdhury, Senior Lecturer, School of Pharmacy, Brac University for their unwavering guidance and encouragement.

Last but not least, I want to say how grateful I am for my parents' support and encouragement, which motivated me to work harder. I also want to say thank you to everyone who has helped me out when I've needed it.

Table of contents

List of tables:

List of Figures:

List of Acronyms

CDRS	Children's Depression Rating Scale-Revised
CL	Confidence interval
ETC	Electroconvulsive therapy
FDA	Food and Drug Administration
GAF	Global Assessment of Functioning scores.
MDD	Major Depressive disorder
MAOI	Monoamine oxidase inhibitors
OCD	Obsessive Compulsive Disorder
PHQ-9	Patient Health Questionnaire
DMS-5	Diagnostic and Statistical Manual of Mental Disorders
SSRIs	Selective serotonin reuptake inhibitors
SNRIs	Serotonin and norepinephrine reuptake inhibitors
SMD	Standardized Mean Difference
TCA	Tricyclic Antidepressants.
TMS	Transcranial magnetic stimulation
VMS	Vagas Nerve Stimulation

Chapter 1

Introduction

A healthy body indicates a sound mind. Our emotional well-being may be positively correlated with maintaining good physical health. However, it is not common. For a wide variety of causes, a large number of individuals suffer from mental illness. Mental illness is a significant issue that we shouldn't disregard. A mental disorder is defined as any illness with significant behavioral or psychological symptoms, together with a painful or unpleasant symptom or a functional impairment in one or more important areas. Nowadays, individuals prioritize their mental and physical health equally. Although mental illnesses have always been common, they are now more visible causes of suffering since many of the terrible physical illnesses that historically afflicted mankind have been eradicated or well treated. A psychiatrist can diagnose a great deal of mental illnesses. Among the mental disorders is major depressive illness. Major depressive illness is now afflicting a large number of persons of all ages.

1.1 Cause

Genetics: Depression is caused by both heritable factors unrelated to personality and heritable factors associated with personality traits that are predisposed to depression, according to study by Kendler et al. 7, 7. Not all forms of depression are heritable, but those with an early onset, severe symptoms, and recurrence may be.8 Serious depression is a complicated illness with several genetic features that cannot be caused by a single gene, according to family research. In studies of pedigrees with multiple major depression cases, chromosomal regions linked to the disorder have been identified. Recurrent, early-onset depression was shown to be associated with chromosome 15q25-q26, according to Holman et al.9, despite the low population-attributable risk. As stated by Galila Agam and R.H. Belmaker, M.D. (2008) Environmental: Stress related to environmental issues is felt more by both younger and older people. Non-chemical environmental stressors, natural disasters, and chemical contaminants all raise the risk of depression. Trauma from the past, continuous stress, tumultuous relationships, and significant losses may also trigger depressive symptoms. Additional medical issues: Individuals with high blood

pressure, diabetes, and hormone abnormalities often have serious depressive illness. Individuals who weigh excessively also have MDD problems. The pathophysiological understanding. Depression stems from a pathological deficit of neurotransmitters, including dopamine, norepinephrine, and serotonin, in the central nervous system. This is known as the monoamine-deficiency hypothesis. The most research on neurotransmitters and depression has focused on serotonin.

1.2 Sign and symptoms

A person will exhibit five or more of the following symptoms, which should manifest almost every day for two weeks and signify a change in the way they had been behaving before: a melancholy attitude; A notable decrease in interest or pleasure in almost all activities (anhedonia); - A notable shift in appetite or weight gain; - Psychomotor agitation or retardation; - Insomnia or hypersomnia; exhaustion or low energy; feelings of shame that are too great or inappropriate; diminished capacity for cognition or focus, hesitation, recurrent suicidal thoughts or fears, or both. (2022, S, Major Depressive Disorder)

1.3.Etiology

Many elements, including those related to biology, genetics, the environment, and the mind, are thought to come together to cause Mdd. There was a time when people thought that problems with the neurotransmitters were the primary reasons for MDD. The extensive usage of antidepressants such selective serotonin receptor inhibitors, dopamine-norepinephrine receptor inhibitors, and serotonin-norepinephrine receptor inhibitors in the treatment of depression provides evidence of this. Low levels of serotonin metabolites have been seen in individuals who have suicidal thoughts. Research has linked the development of depression to the inhibitory neurotransmitter GABA as well as the main excitatory neurotransmitters glutamate and glycine. For instance, research on genetics has shown that the likelihood of concordance for MDD is rather high among monozygotic twins. Research has shown that other factors such as life experiences and personality characteristics have a significant role. GABA levels in the brain, cerebrospinal fluid and plasma decreased.

1.4.Epidemiology

Major depressive illness is a relatively frequent mental condition. Women have almost double the prevalence rate of men. The reasons for this disparity have been identified as hormonal fluctuations, childbearing effects, gender-specific psychosocial stressors, behavioral models

of learned helplessness, and delivery-related outcomes. Although the typical age of start is about 40 years old, overuse of alcohol and other drugs has been linked to growing occurrence in younger groups, according to recent research. MDD is more common in those with no close relationships and in those who have recently divorced, split, or lost a loved one. The prevalence of MDD is the same across all racial and socioeconomic categories. People with Major Depressive Disorder (MDD) often have co-occurring disorders, including obsessive-compulsive disorders, panic disorders, substance use disorders, and social anxiety disorders. Suicide risk is increased in MDD patients who also have certain comorbid illnesses. Elderly people with comorbid medical issues are more likely to experience depression. Depression has been shown to be more prevalent in rural than in urban areas.(S, *Major depressive disorder* 2022)

1.5.History

Major depressive disorder is mostly diagnosed clinically based on the patient's mental state assessment and clinical history. The patient's medical history, family history, social history, and history of drug use must all be included in the clinical interview in addition to the symptomatology. Consulting the patient's friends and family for more information is an essential part of the psychiatric assessment process. There should be a comprehensive physical examination, which includes a neurological assessment. It's important to screen out any underlying medical or biological causes for a depressed illness. It is important to get a complete medical history as well as a family medical and psychiatric history. The mental state assessment is a crucial component in the diagnosis and evaluation of MDD.(S,*Major,depressive,disorder*2022)

1.6 Evaluation

Patients with depression often see their primary care physician instead of a mental health specialist when physical symptoms of depression appear. Patients often deny experiencing depressive symptoms, and their families or employers will frequently refer them to therapy so they may be assessed for social disengagement and decreased activity. Every time a patient comes in, it's critical to screen them for thoughts of suicide or homicide. Primary care settings often use the Patient Health Questionnaire-9 (PHQ-9), a self-report, standardized depression rating scale, for MDD screening, diagnosis, and treatment response monitoring. Nine elements on the PHQ-9, which measures psychosocial impairment, match the DSM-5 criteria for major depressive disorder. A PHQ-9 score of 10 or above, which ranges from 0 to 27, suggests a potential MDD. (S, *Major depressive disorder* 2022)

1.7 Aim of the study

This research aims to give a summary of MDD as well as a concise review of the available targeted therapies for MDD and the clinical outcomes of these treatments.

1.8 Rational of the study

Major depressive disorder (MDD) is a widespread and unpleasant mental disease that is listed as one of the top five causes of disability in Western countries by the World Health Organization. MDD may affect people of any age, although it can progress more severely in childhood than in later life, resulting in longer depressive episodes, increased suicidality, and more hospital admissions. The information about MDD, the information required for its prevention, and the information about its treatments was the aim of this thesis, which may aid individuals in learning more about MDD and the significance of its prevention.

Chapter2

Methodology

With the use of papers and publications from current journals, this review was created. Trials and publications related to clinical studies were regularly examined. Data was obtained from PubMed and Google Scholar. "MDD", "information about MDD", "types of MDD", "treatment of major depressive disorder", "ECT", "TMS", "psychiatry", and "therapist of “MDD" were the search terms used to get the material. FDA was looked up for the disease's therapy.

Chapter 3

Differential diagnosis

To effectively treat Major Depressive Disorder (MDD), it is essential to rule out other medical conditions, bipolar disorder, schizoaffective disorder, schizophrenia, anxiety disorders, eating disorders, bereavement, substance or medication-induced depressive disorders, dysthymia, cyclothymia, and adjustment disorder with depressed mood. The following variables may cause depression symptoms to arise as a secondary symptom:(2022, S, Major Depressive Disorder) Neurological disorders such as multiple sclerosis, Parkinson's disease, Alzheimer's disease, subdural hematomas, epilepsy, and cerebrovascular accidents are among the causes (S, Major depressive disorder 2022). anomalies of the endocrine system, such as diabetes, adrenal dysfunction, and thyroid issues (S, Major depressive disorder 2022) Some metabolic illnesses include hyponatremia and hypercalcemia (S, Major depressive disorder 2022). Drugs and chemicals that individuals abuse include steroids, antihypertensives, anticonvulsants, antibiotics, sedatives, hypnotics, alcohol, and stimulant withdrawal (S, Major depressive disorder 2022). inadequacies in nutrition, such as those brought on by low levels of iron, folate, vitamin B12, vitamin D, or vitamin B6 (S, Major depressive disorder 2022) Contagious diseases include syphilis and HIV (S, Major depressive disorder 2022). Tumors (S, Major Depressive Disorder, 2022). The tremendous variability of MDD makes it difficult to classify and determine the specificity of treatment. These days, models include all forms of depression into one group. Nonetheless, the notion of Major Depressive Disorder obscures important differences between severe illnesses requiring medication and mild to moderate disorders that may be treated with psychotherapy or completely cured on their own. For individuals with mild-to-moderate MDD, routine or too strong treatment is employed (Paris, 2014).To assess vortioxetine's safety and effectiveness in teenagers suffering from major depressive disorder (MDD)(Findling et al., n.d.)

Chapter 4

Treatment

MDD may currently be treated in a variety of ways. Among them include electroconvulsive therapy (ECT), psychotherapy, antidepressants, and other somatic therapies (Fava & Kendler, 2000). Table 1 lists the techniques (as well as disadvantages) of each kind of treatment. The efficacy of alternative somatic therapies has not been shown; ECT is a highly successful therapy, but its use is often limited to MDD patients who are psychotic or very resistant to treatment. In the realm of psychotherapy, the two time-limited treatment methods that have consistently shown success in treating major depressive disorder (MDD) are cognitive therapy and interpersonal psychotherapy. After conducting double-blind, placebo-controlled studies, the FDA approved 21 drugs for the treatment of depression, proving that pharmacotherapy is an effective way to treat (MDD). There are several factors that have complicated the effectiveness of depression medications currently on the market and those under research, including the relatively high rates of response to placebo in controlled trials, the short treatment duration in some studies, and the frequent use of outcome measures that have a lower sensitivity to distinguish between active and inactive treatments(Fava & Kendler, 2000)

SSRIs: Citalopram, Dapoxetine, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine

SNRIs: Desvenlafaxine, Duloxetine, Levomilnacipran, Milnacipran, Venlafaxine

TCA: Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine, Amoxapine

MAOIs: Isocarboxazid, Phenelzine, Selegiline, Tranylcypromine

4.1 table 1: Mechanism of action:

SSRI	SNRI	MAOI	TCA
inhibit serotonin reuptake ↓ resulting in higher neurotransmitter concentrations in the synaptic cleft and activating pre- and post-synaptic 5HT receptors to trigger a therapeutic reaction.	prevent serotonin and norepinephrine from being reabsorbed. ↓ after being released from the cleft of synapses.	preventing the presynaptic terminals' reuptake of serotonin and norepinephrine ↓ causing these neurotransmitters to be more concentrated in the synaptic cleft.	inhibiting the enzyme monoamine oxidase ↓ breaks down the following neurotransmitter classes from the brain: tyramine, dopamine, serotonin, and norepinephrine. ↓ breaks down the brain's tyramine, dopamine, serotonin, and norepinephrine neurotransmitter classes.



Figure 1: MOA of SSRIs.

4.2 table 2: Various medications and their requirements:

Drug	**Side effects**	**Pharmacokinetics and pharmacodynamics**	**Dosage and administration**	**Precautions**	**Special population**
Fluoxetine	Nauseaanorexia, insomnia, and nervousness (Wood & Gram, 1994)	While the half-life of norfluoxetine, the metabolite of fluoxetine, spans from 7 to 15 days, fluoxetine's half-life is around 1 to 4 days. There is a nonlinear pharmacokinetic profile to fluoxetine. (Altamura et al., 1994)	20 mg capsule(Davey et al., 2019)	high risk people those with bleeding or acid-peptic illness (Andrade et al., 2010a)	Poor appetite, depression in different diagnostic subgroups,concurrent clinical conditions, teenage with depression, and OCD patients; its long-term (maintenance) effectiveness (Stokes & Holtz, 1997)

Vilazodone	diarrhea, nausea, vomiting, and insomnia(Culang-Reinlieb et al., 2012)	20-mg dose 14 days(Boinpally et al., 2013)	10 mg once day and gradually increased to the recommended goal daily dosage of 20x2 mg over a period of 14 day(Choi et al., 2012)	Food must be consumed in order to maximize bioavailability. (Guay, 2012)	MDD and anxiety disorders(Guay, 2012)
Sertraline	Among youths aged 18–24, the risk of suicide is on the rise..(Shinohara et al., 2019)	A weakly active metabolite known as N-desmethyl-sertraline is formed during the sluggish absorption of sertraline after oral administration.Higher conc in plasma than the parent drug does at fast(DeVane et al., 2002)	50 and 150 mg/day(DeVane et al., 2002)	individuals with a predisposition for complications, such as a history of bleeding or acid reflux,(Andrade et al., 2010b)	panic disorder, ocd and post-traumatic stress disorder(DeVane et al., 2002)

Duloxetine	nausea/vomiting, diarrhoea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite and dry mouth(Oliva et al., 2021)	Several factors have been shown to influence the way duloxetine is absorbed and distributed in the body, including a patient's age, ethnicity, smoking status, hepatic and renal function, and cytochrome P450 (CYP) 2D6 genotype..(Knadler et al., 2011)	47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.(Knadler et al., 2011)	giving people with MDD medications to help them stick to their treatment plans and have better results. (Oliva et al., 2021)	Mdd, problems with the nervous system caused by diabetes, stress fluid incontinence, GAD, and fibromyalgia (Knadler et al., 2011)

Chapter 5

Clinical trial

MDD is characterized by a persistently low feelings and a loss of enjoyment in activities that were once enjoyable. Other symptoms of major depression include changes in appetite or weight, trouble sleeping or excessive sleeping, psychomotor agitation or retardation (feeling restless, sluggish, or lacking energy), inappropriate guilt or feelings of worthlessness, poor concentration, and thoughts of death or suicide, according to the DSM-5.There are pharmacologic and non-pharmacologic approaches to treating depression. Our overarching objective is to alleviate problems.

Table :3 Characteristics of included review:

Title	**Authors**	**Last assessed as up to date**	**No of the studies range of the follow up**	**Study range size sample**	**Population**	**Interventions**	**Comparisons**	**Outcomes**
TCAs	Hazell P, O'Connell D, Heathcote D, Henry DA	February 2008	13	6-182	Treatment for depression in patients (ages 6–18) with an IQ more than or equal to 80	amitnptyline 80 mg twice day or 300 mg one day for depression. 150 mg/kg/day	Not active placebo	Principle: one "best available" result; selection based on ratings using five criteria: appropriateness to paediatrics, reliability, construct validity, agreement

						of desipramine, 200–300 mg/day of imipramine, or 5 mg/kg/day of nortriptyline, as needed to prevent plasma level fluctuations		with dinical interview, and research record.
			4 to 10wk		Studies of mixed youth and adults subject were not included		One study included an additional comparison with paroxitine	Secondary: side effects
SSRIs	Hetrick SE, Merry SN, McKenzie J, Sindahl P.	March 2007	12	96-439	Children and adolescents (aged 6- 18) with an 10 > = 70, both in and outpatients, who were	Daily oral treatment paroxetine, fluoxetine	Inactive placebo	Primary: remission of depressive disordder and suicide

	Procto r M				diagnosed by a clinician and met DSM or ICD critena for a primary diagnosis of depressive disorder.	(+), citalo pram, escita lopra m oxalat e. and sertral ine.		completio n
			7-12w k					Outcomes Secondary objectives include depressio n symptoms ; study protocol completio n (as a proxy for treatment acceptanc e); negative outcomes; and suicide-rel ated outcomes (including suicide-rel ated behaviour and the Soong Cheaters Global Assessme nt Scale, which

								measures academic performance, cognitive abilities, and social support).
Exercise	Larun L, Nordheim LV. Ekeland E, Hagen KB. Heian F	May 2006	11	11-387	(aged 0 to 20), with or without depression. Trials involving children and youth with	Vigorous exercise: aerobic exercise such as walking, running, aerobics for weightlifting	Exercising vigorous aerobic activity like jogging, walking, or aerobics (8 studies) or resistance training with weights (3 studies).	Primary: depression symptoms post-treatment
			6-40wk		psychotic or borderline conditions, autism, exercise physical handicap, eating. disorders or chronic somatic diseases were excluded. All kinds of settings were included.		• Psychosocial interventions: Discussion group or group counselling.	Secondary: prevalence depression

Table :3

Title	Authors	Search Strategy	Methodological Quality
Tricyclic Drugs	Hazell P, O'Connell D, Heathcote D, Henry DA	Research in the fields of CCDANCTR-Studies and CCDANCTR-References was conducted on December 2, 2008. doing a literature review using MEDLINE. We looked at abstracts written in English from studies that were published in English and those that were not. The bibliographies of previously published reviews and articles detailing original research were cross-checked. In order to gather data for the meta-analysis, we reached out to the writers of relevant abstracts published the American Academy of Child and Adolescent Psychiatry conference. A search was conducted manually via the Journal of the American Academy of Child and Adolescent Psychiatry	A comprehensive set of twelve criteria was used to assess the study, with a maximum score of 36. The outcome: The methods used to hide allocations and ensure randomization were poorly described main studies. Only three studies published however a fourth may have been conducted.Four studies had values of 27 or 28, two had scores of 18, and seven had scores ranging from 22 to 25. There is no indication or discussion on how to interpret these total ratings by the writers.
SSRIs	Hetrick SE, Merry SN, McKenzie J, Sindahl P. Proctor M	There was an audit of the trial register for the CCDAN organization. • PSYCINFO (years 1886–2005) • From 1966 until October 2005, MEDLINE was available.	the number of individuals who dropped out or withdrawn from the study, the secrecy of treatment assignments, and the ability to keep participants informed about the

		• Central Chapter of the Cochrane Library, Second Edition, 2004 inside the examined online datasets. Pharmaceutical company trial databases were also perused. We perused the papers' and reviews' reference lists that surfaced throughout the search. The primary journals most likely to publish trials in this field were identified by manual journal searches using MEDLINE and subject matter experts. They were included because they were available and because no previous hand-searching was done. Our group's assignment was to read the sessions' proceedings from the AACP annual conference. Reference lists were reviewed, important researchers were contacted by letter, and online resources were investigated. Research on fluoxetine benefited from extra data supplied by Eli Lilly.	intervention and its results were the criteria used to evaluate the trials. Another tool for gauging potential bias was the quality score developed by Moncrieff and colleagues. In addition to possible reporting bias, other forms of bias were examined, including pharmacological support, compliance, and others. Official total scores were not calculated. End result Between 17 and 46 percent of take part in the control group and 17 to 40 percent in the treatment patients dropped out of the two trials, respectively. A key source of concern in the fluoxetine trials was the disparity in the rates of treatment group dropouts. Every single author acknowledged the existence of intention-to-treat (ITT) research. As far as we can tell, only two of the trials included all of the randomly assigned patients.

			Evaluations are conducted on a lesser number of patients in the alternative trials compared to the selected group. A minimum of one dosage of medicine, a placebo, or a post-baseline evaluation of safety or efficacy was typically required for analysis in most trials. There were no comprehensive allegations of allocation fraud in any of the studies that were examined. All of the trials' treatment groups were supposedly "double blind," meaning that researchers did not know which group was which. According to the blinded accounts of the two trials, the SSRI and placebo medications were identical. The term "double blind" is used to describe the presence of both "blind" independent assessors, although nothing is known about the methods used to blind the participants in the three trials. Concerning the

			efficacy of blinding, no study reported it.
Exercise	Larun L, Nordheim LV. Ekeland E, Hagen KB. Heian F	ERIC Webspirs (1965–2005), Cochrane Controlled Trials Register (via Wiley, latest issue available), EMBASE OVID (1980–2005), SportDiscusWebspirs (1949–2005), CINAHL OVID (1982–2005), and MEDLINE Ovid (1966–2005) were all searched. Relevant references were filtered from references in included papers and reviews. Academics and professionals in the area were asked to participate in ongoing and unpublished studies.	We used seven criteria to determine internal validity. Creation of allocation sequences, concealment of co-interventions with allocation, comparison of baselines, and intention-to-treat analysis. as a means of following up while concealing the situation from the person reviewing the results. This technique does not adhere to criteria such as maintaining the anonymity of physicians and patients. Each piece of research was given an excellent, moderate, or bad rating. End result: Tragically, no top-notch papers were located. Six studies were classified as having moderate or poor quality, with scores of 3 or 4.

TCAs and placebos: When comparing the effects of on the severity of depression in children and adolescents, researchers discovered no statistically significant changes. There was no statistically significant difference between the treatment and control groups with regard to adverse effects such as fatigue, insomnia, headaches, heart rate, perspiration, constipation, or urine issues. Active treatment individuals were much more likely to have vertigo orthostatic hypotension, tremor, and dry mouth compared to placebo participants. We did not estimate the overall negative consequences.

SSRIs to a placebo: Comparing it, we find that fluoxetine has a different effect on children and adolescents than placebo and on teenagers. Patients treated with paroxetine, sertraline, or citalopram showed no statistically significant differences between the groups. No changes children and adolescents who were given Paxil, fluoxetine, or a placebo when it came to measuring how well individuals were working (using the Global Assessment of functioning (GAF) scores). Headaches, nausea, and vertigo were among the most frequently reported side effects. Mood swings, inability to sleep, and lethargy were other common complaints. Adverse events were more likely to occur to both children and teenagers who used SSRIs. Table 4 is a comprehensive breakdown of all the negative information about SSRIs.

Treatment vs. no treatment: social problem assistance or low-intensity exercise. Teens and children who exercised, did nothing, exercised at a low level, or received psychiatric interventions did not vary substantially in terms of changes in the degree of sorrow.One group was compared to the general population, and the other to those who were at risk. Exercising compared to doing nothing and exercising compared to psychological therapy were the two groups compared. Although the authors did not collect data on negative outcomes, they did state that exercise often had minimal negative effects.

5.2 Discussion:

TCAs: According to the CDS research, TCAs aren't a suitable option for treating depression in preteens and teenagers. Since one research found no improvement in treatment outcomes when TCAs were used in this setting, it is easy to argue that youth who have not responded to other pharmacological or talk therapy interventions for depression should not be given TCAs. There are a number of negative side effects to these medications, including heart damage from overdose, so it's important to keep that in mind while treating adolescent depression. This means they aren't appropriate for use in adolescent depression treatment.

In the case of children and adolescents, there is a lack of conclusive data on the efficacy of selective SSRIs compared to placebo. The significance of this variation is uncertain, and the investigations are limited by the short intervals between visits and the significant placebo reactions among the participants. SSRIs might increase risk of suicide-related behaviors, the significance of this finding is debatable since the decline occurred before the prescription of SSRIs began to rise. Together with the family, clinicians should discuss the child's or teen's treatment choices, including the pros and drawbacks of SSRIs, the dangers of untreated depression, and other possible outcomes. It is important to closely monitor the risk of suicide, especially in cases when medication is being taken. A diagnosis of dysthymia, severe depression, or cognitive despair is associated with an increased risk of suicide behavior in young people. Suicide attempts and completions, as well as difficulties with social and academic functioning, are related with untreated major depressive illness. Treatment with an SSRI may or may not significantly alter this risk, however. To properly evaluate the efficacy of SSRIs and the risk-benefit ratio, future research should put proper data on self-harm measures, depressive symptoms scale, and functional outcome across time. These concerns have been attempted to be addressed by recent published research that were not included of the most recent SSRI Cochrane Review. It has been suggested in an ecological study using population data that using SSRIs may reduce the chance of suicide. Serum investigations of juvenile suicide victims did not reveal the presence of SSRIs, according to postmortem research. Nonetheless, it is important to keep an eye on young people who are given SSRIs for the sake of individual risk management, since this indicates a difference in the population.

When it comes to adolescents and teenagers as a whole, there doesn't seem to be any statistically significant evidence that exercise reduces depression levels. There isn’t much

research that examine this issue, and the ones that do utilize extremely diverse assessment techniques, treatments, and participants, making it difficult to make unambiguous conclusions. It makes no difference whether the exercise is simple or difficult. When it comes to mental health, the CDS lacks the data to determine whether exercise or weight training is superior. Children and teenagers in care do not have a wealth of data. Although exercise should not be used to treat severe depression, it might help kids and teenagers feel better about their health and self-esteem since, when done appropriately, it has no known adverse consequences and many good impacts on physical health.

Chapter 6

Conclusion

Even though major depressive illness is still a neglected mental health issue, it has become more problematic for the general public. Many people who suffer with this illness, however, choose not to voice their concerns. Consequently, doctors make incorrect diagnosis since they don't know the full scope of the sufferer’s sign. Doctors need to be friendly enough with their patients, so they feel comfortable enough to discuss sensitive issues openly. There are a plethora of tests and procedures that doctors should recommend in order to diagnose mental illness. And so it is that they ought to provide antidepressants to the patients. It is important to monitor the adverse effects. This antidepressant has a lot of side effects, therefore you should stay away from it. When dealing with mild to severe depression, psychotherapy should be the first course of treatment. Patients' loved ones should also be informed about their condition.

Reference

Altamura, A. C., Moro, A. R., & Percudani, M. (1994). Clinical Pharmacokinetics of Fluoxetine. *Clinical Pharmacokinetics*, *26*(3), 201–214. https://doi.org/10.2165/00003088-199426030-00004

Andrade, C., Sandarsh, S., Chethan, K. B., & Nagesh, K. S. (2010a). Serotonin Reuptake Inhibitor Antidepressants and Abnormal Bleeding. *The Journal of Clinical Psychiatry*, *71*(12), 1565–1575. https://doi.org/10.4088/JCP.09r05786blu

Andrade, C., Sandarsh, S., Chethan, K. B., & Nagesh, K. S. (2010b). Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. *The Journal of Clinical Psychiatry*, *71*(12), 1565–1575. https://doi.org/10.4088/JCP.09r05786blu

Boinpally, R., Alcorn, H., Adams, M. H., Longstreth, J., & Edwards, J. (2013). Pharmacokinetics of Vilazodone in Patients with Mild or Moderate Renal Impairment. *Clinical Drug Investigation*, *33*(3), 199–206. https://doi.org/10.1007/s40261-013-0061-5

Choi, E., Zmarlicka, M., & Ehret, M. J. (2012). Vilazodone: A novel antidepressant. *American Journal of Health-System Pharmacy*, *69*(18), 1551–1557. https://doi.org/10.2146/ajhp110374

Culang-Reinlieb, M. E., Sneed, J. R., Keilp, J. G., & Roose, S. P. (2012). Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. *International Journal of Geriatric Psychiatry*, *27*(8), 777–784. https://doi.org/10.1002/gps.2783

Davey, C. G., Chanen, A. M., Hetrick, S. E., Cotton, S. M., Ratheesh, A., Amminger, G. P., Koutsogiannis, J., Phelan, M., Mullen, E., Harrison, B. J., Rice, S., Parker, A. G., Dean, O. M., Weller, A., Kerr, M., Quinn, A. L., Catania, L., Kazantzis, N., McGorry, P. D., & Berk, M. (2019). The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomized, double-blind, placebo-controlled, multicentre clinical trial. *The Lancet Psychiatry*, *6*(9), 735–744. https://doi.org/10.1016/S2215-0366(19)30215-9

DeVane, C. L., Liston, H. L., & Markowitz, J. S. (2002). Clinical pharmacokinetics of sertraline. *Clinical Pharmacokinetics*, *41*(15), 1247–1266. https://doi.org/10.2165/00003088-200241150-00002

Fava, M., & Kendler, K. S. (2000). Review Major Depressive Disorder tions in "first-world" countries such as the United States. In *Neuron* (Vol. 28).

Findling, R. L., Delbello, M. P., Zuddas, A., Emslie, G. J., Ettrup, A., Petersen, M. L., Schmidt, S. N., & Rosen, M. (n.d.). *Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study*. www.jaacap.org

Gorlyn, M., Keilp, J., Burke, A., Oquendo, M., Mann, J. J., & Grunebaum, M. (2015). Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion. *Psychiatry Research*, *225*(3), 407–412. https://doi.org/10.1016/j.psychres.2014.12.004

Guay, D. R. P. (2012). Vilazodone Hydrochloride, a Combined SSRI and 5-HT1A Receptor Agonist for Major Depressive Disordersts. *The Consultant Pharmacist*, *27*(12), 857–867. https://doi.org/10.4140/TCP.n.2012.857

Knadler, M. P., Lobo, E., Chappell, J., & Bergstrom, R. (2011). Duloxetine: clinical pharmacokinetics and drug interactions. *Clinical Pharmacokinetics*, *50*(5), 281–294. https://doi.org/10.2165/11539240-000000000-00000

Oliva, V., Lippi, M., Paci, R., Del Fabro, L., Delvecchio, G., Brambilla, P., De Ronchi, D., Fanelli, G., & Serretti, A. (2021). Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *109*, 110266. https://doi.org/10.1016/j.pnpbp.2021.110266

Paris, J. (2014). The Mistreatment of Major Depressive Disorder. In *CanJPsychiatry* (Vol. 59, Issue 3). www.TheCJP.ca

Rosenblat, J. D., Kakar, R., & McIntyre, R. S. (2015). The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *The International Journal of Neuropsychopharmacology*, *19*(2). https://doi.org/10.1093/ijnp/pyv082

Shinohara, K., Efthimiou, O., Ostinelli, E. G., Tomlinson, A., Geddes, J. R., Nierenberg, A. A., Ruhe, H. G., Furukawa, T. A., & Cipriani, A. (2019). Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. *BMJ Open*, *9*(5), e027574. https://doi.org/10.1136/bmjopen-2018-027574

Stokes, P. E., & Holtz, A. (1997). Fluoxetine tenth anniversary update: the progress continues. *Clinical Therapeutics*, *19*(5), 1135–1250. https://doi.org/10.1016/S0149-2918(97)80066-5

Wood, A. J. J., & Gram, L. F. (1994). Fluoxetine. *New England Journal of Medicine*, *331*(20), 1354–1361. https://doi.org/10.1056/NEJM199411173312008